Some rough notes from Q2’23 call. Missed the first few minutes of mgmt update
capacity utilization : 95%
Capex : 200 cr. in 2 to 3 years, period starting from last year when it was announced. (to be funded mostly by internal accrual).
API block (capex : 40 cr.) : To be ready by end of next year (end of Q2’FY24). Market in RoW, US, domestic market too. So once plant is ready, some business can start, while regulatory approval work is getting done for regulated markets.
Fermentation Block (Capex : 160 cr, 3 plants, in phased manner over next 2 to 3 years, no capex done so far, project is under planning. Plan to start work by next month): By end of next to next year.
Asset Turn : Not thinking in terms of asset turns, but payback period 3 to 4 years.
New Product (under development) : product details not in public domain. Looking for products with lesser competition. May have dozen products in development, but very careful in what we want to make commercial.
Existing Product : No guidance on margins as pricing is not under their control. Don’t want to speculate on pricing.
New customers : 2 to 3 added but volume is low
Tuberculosis : Tender driven business so if tenders don’t open then business volume can get impacted. But overall worldwide the number of patients remain stable.
Competitor: has filed DRHP seeking double the valuation. (which one ?)
| Subscribe To Our Free Newsletter |
